Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
- D. Klionsky, K. Abdelmohsen, S. Zughaier
- BiologyAutophagy
- 18 April 2012
There continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes, so it is important to update guidelines for monitoring autophagic activity in different organisms.
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways
- T. Chou, Steven J Brown, R. Deshaies
- Biology, ChemistryProceedings of the National Academy of Sciences
- 7 March 2011
N2,N4-Dibenzylquinazoline-2,4-diamine (DBeQ) was identified as a selective, potent, reversible, and ATP-competitive p97 inhibitor that blocks multiple processes that have been shown by RNAi to depend on p97, including degradation of ubiquitin fusion degradation and endoplasmic reticulum-associated degradation pathway reporters.
Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA Domain Ubiquitination.
- Youjin Lee, T. Chou, S. Pittman, Amy L Keith, B. Razani, C. Weihl
- BiologyCell Reports
- 4 April 2017
Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains.
- T. Chou, Stacie L. Bulfer, M. Arkin
- Biology, ChemistryJournal of Molecular Biology
- 29 July 2014
A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease.
- Michael A. Gonzalez, S. Feely, M. Shy
- Medicine, BiologyBrain : a journal of neurology
- 1 November 2014
Functional studies showed that the Glu185Lys variant impaired autophagic function leading to the accumulation of immature autophagosomes, and should be considered for genetically undefined Charcot-Marie-Tooth disease type 2.
Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase
- T. Chou, Kelin Li, K. Frankowski, F. Schoenen, R. Deshaies
- Biology, ChemistryChemMedChem
- 11 January 2013
The results nominate ML240 as a promising starting point for the development of a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway‐specific p97 inhibitors.
Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins.
- T. Chou, J. Baraniak, C. Wagner
- Biology, ChemistryMolecular Pharmaceutics
- 12 January 2007
The differential substrate specificity observed for human and E. coli enzymes represents a potential therapeutic rationale for the development of selective antibiotic phosphoramidate pronucleotides.
Altered cofactor regulation with disease-associated p97/VCP mutations
- Xiaoyi Zhang, Lin Gui, T. Chou
- BiologyProceedings of the National Academy of Sciences
- 16 March 2015
The results show that cofactors play a critical role in controlling p97 ATPase activity, and suggest that lack of cofactor-regulated communication may contribute to p97-associated disease pathogenesis.
Quantitative Cell-based Protein Degradation Assays to Identify and Classify Drugs That Target the Ubiquitin-Proteasome System*
- T. Chou, R. Deshaies
- BiologyJournal of Biological Chemistry
- 22 February 2011
This work establishes a high-throughput screening-compatible pipeline for identification and classification of small molecules, cDNAs, or siRNAs that target components of the ubiquitin-proteasome system.
...
...